IllustrativePoolbeg Pharma - POLB 001 Trial Activated as CRS Prevention Study Moves Into Patients
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
A clinical trial for POLB 001 has been activated, marking the study's progression into the patient phase. The trial is focused on preventing cytokine release syndrome, or CRS. The study's activation indicates that it is moving forward with testing in patients.